Evoq Remedies Ltd — Others, 26-08-2025: Others

Evoq Remedies has submitted its Annual Report for FY 2024-25, with its 15th Annual General Meeting set to adopt financial results and consider re-appointing a director and auditor. Shareholders will also vote on approving material related party transactions, each up to 50 Cr, with eight entities. For FY2025, revenue grew to 11.76 Cr (from 4.05 Cr), but net profit decreased to 0.09 Cr (from 0.45 Cr). Auditors flagged significant non-compliance with loan provisions (25.06 Cr to related parties), unpaid taxes (1.04 Cr total), outstanding related party debtors, and SEBI investigations regarding fund utilization and financial statements.